Jimandin

Sitagliptin, the active ingredient in Jimandin, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults, helping to control blood glucose levels when used with diet and exercise.

GNH USA supplies Jimandin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jimandin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus. It helps improve glycaemic control through several therapeutic approaches. - Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels when combined with diet and exercise. - Monotherapy in metformin‑intolerant patients: provides effective glucose control as a single oral agent. - Combination therapy with other oral antidiabetics: enhances overall glycaemic management when added to agents such as metformin or sulfonylureas.

Adverse reactions to Jimandin may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Nasopharyngitis: symptoms of common cold. - Upper respiratory tract infection: cough, sore throat. - Diarrhoea: loose stools. - Arthralgia: joint pain.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate care. - Severe allergic reactions: anaphylaxis, angioedema. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: extensive skin detachment. - Hepatic injury: elevated liver enzymes or jaundice. - Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes. - Bullous pemphigoid: autoimmune blistering skin disease.

Before initiating therapy, clinicians should consider several safety aspects. - Renal impairment: dose adjustment may be required based on eGFR. - Hepatic impairment: monitor liver function tests regularly. - History of pancreatitis: avoid use due to risk of recurrence. - Concomitant insulin or sulfonylureas: increased risk of hypoglycaemia; monitor glucose closely. - Pregnancy and breastfeeding: safety not established; use only if benefit outweighs risk. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Sitagliptin may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Insulin: may cause significant hypoglycaemia. - Sulfonylureas (e.g., glipizide): increased risk of hypoglycaemia. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): can raise sitagliptin plasma levels.

Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor renal function and potassium levels. - Diuretics: watch for electrolyte disturbances. - Rifampin: may reduce sitagliptin effectiveness by inducing metabolism.